Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675734 | 0.83 | F10 (0.54) | F10 | |
| SCHEMBL803332 | 0.82 | CKS1B (0.56) | F10 | |
| SCHEMBL785158 | 0.79 | F10 (0.53) | F10 | |
| SCHEMBL12046788 | 0.79 | DRD2 (0.54) | — | |
| SCHEMBL7088909 | 0.74 | F10 (0.48) | F10 | |
| SCHEMBL13083096 | 0.74 | F10 (0.47) | F10 | |
| SCHEMBL5842753 | 0.74 | BDKRB1 (0.51) | F10 | |
| SCHEMBL785012 | 0.73 | ROCK2 (0.54) | F10 | |
| SCHEMBL8126582 | 0.73 | F10 (0.49) | F10 | |
| SCHEMBL23138432 | 0.73 | DRD2 (0.50) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | F10 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.